Suk Ho Lee

Title: Suk Ho Lee: Innovator in Histone Deacetylase Inhibitors

Introduction

Suk Ho Lee is a prominent inventor based in Kwangmyung-shi, South Korea. He has made significant contributions to the field of medicinal chemistry, particularly in the development of novel compounds with therapeutic applications. With a total of 2 patents, his work focuses on innovative solutions for cancer treatment.

Latest Patents

One of his latest patents involves α,β-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors. This invention discloses agents that inhibit histone deacetylase, specifically novel hydroxamic acid derivatives or pharmaceutically acceptable salts that serve as anticancer agents based on their histone deacetylase inhibitory activity. Another significant patent pertains to pyrrolopyrimidinone derivatives, detailing a series of compounds and their preparation processes, which also have potential therapeutic uses.

Career Highlights

Throughout his career, Suk Ho Lee has worked with notable companies such as SK Chemicals Co., Ltd. and In2gen Co., Ltd. His experience in these organizations has allowed him to advance his research and contribute to the development of innovative pharmaceutical products.

Collaborations

Suk Ho Lee has collaborated with esteemed colleagues, including Dae-Kee Kim and Ju Young Lee. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic agents.

Conclusion

Suk Ho Lee's contributions to the field of medicinal chemistry, particularly in the area of histone deacetylase inhibitors, highlight his innovative spirit and dedication to advancing cancer treatment. His patents and collaborations reflect a commitment to improving therapeutic options for patients.